Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering...
News
Mesa Labs Completes the Acquisition of GKE Science & Technology Co.
LAKEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader...
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065...
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie,...
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
Dr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the RoleST. LOUIS and SAN DIEGO, Jan. 03,...
OGM Added to International System for Human Cytogenomic Nomenclature
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of...
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
HORSHAM, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder...
Collegium Provides 2024 Financial Guidance
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected...
Safety Shot to Garner Global Exposure with its Brand Activation Event at Coachella—One of the Top Music Festivals in the World
Safety Shot, Inc. Safety Shot to Garner Global Exposure with its Brand Activation Event at Coachella Set to be highlight...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal...
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
JERUSALEM, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics...
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
Agreement provides potential opportunity for oncology patients to have access to improved therapiesBOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Elektrofi,...
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a...